Business Context and Reporting Period
This Form 8-K, filed on December 30, 2019 (reporting events of January 2, 2020), concerns Intrexon Corporation (trading symbol: XON), which announced plans to change its name to Precigen, Inc. The filing details a major corporate restructuring involving the sale of non-healthcare bioengineering assets and a concurrent private placement of common stock to TS Biotechnology Holdings, LLC, an entity managed by Third Security, LLC.
Key Financial Metrics and Liquidity
- Asset Sale Proceeds: Binding agreements executed to sell non-healthcare assets for an aggregate purchase price of $53 million plus contingent payment rights, plus a separate sale of a 50% interest in EnviroFlight for $12.2 million.
- Equity Financing: Agreement to sell up to $35 million of common stock to TS Biotechnology.
- Cash Position: Preliminary estimate of cash, cash equivalents, and short-term investments as of December 31, 2019, was $75 million.
- Projected Liquidity: Management estimates that upon closing the transactions, the company would have held approximately $175 million in cash and equivalents.
- Revenue and Profit: The filing does not provide specific revenue, profit, or margin figures for the period; these are reserved for the upcoming Form 10-K.
Material Changes and Transactions
- Leadership Transition: Helen Sabzevari, Ph.D., was appointed President and CEO effective January 1, 2020. Former CEO Randal J. Kirk transitioned to Executive Chairman.
- Asset Divestiture: Intrexon agreed to sell the majority of its bioengineering assets (including interests in Blue Marble AgBio, Oragenics, and others) to TS Biotechnology. The deal includes a "go-shop" period allowing Intrexon to solicit alternative proposals until January 31, 2020.
- Contract Expiration: The Services Agreement with Third Security, LLC, which provided support services to the previous CEO, expired on January 1, 2020, and was not extended.
- Ownership Structure: Prior to the transactions, Randal J. Kirk and affiliates beneficially owned approximately 46% of voting stock. Third Security was deemed to beneficially own approximately 35% of common stock.
Outlook, Risks, and Contingencies
Management expects to close the asset sale and stock subscription transactions on January 31, 2020, subject to customary closing conditions, including the completion of a corporate restructuring. The filing includes significant forward-looking statements regarding the success of these transactions, the company's cash position, and the leadership transition.
Key Risks and Contingencies:
- Closing conditions for the asset sale and stock subscription may not be satisfied.
- There is no assurance that Intrexon will receive or negotiate alternative proposals during the "go-shop" period.
- Risks associated with separating businesses from ongoing operations and potential distraction of management.
- Volatility in stock price and market conditions.
Investor Verification Checklist
- Verify the final closing date of the Stock and Asset Purchase Agreement and the Subscription Agreement.
- Confirm the final purchase price per share for the $35 million stock sale, which is based on a volume-weighted average price calculation period.
- Review the upcoming Form 10-K for audited financial results for the year ended December 31, 2019.
- Monitor for any "Alternative Proposals" received during the go-shop period that might alter the transaction terms.
- Confirm the official name change to Precigen, Inc. and the associated ticker symbol updates.